Targeting CCR2/5 in the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis
by Lefere, Sander, Devisscher, Lindsey and Tacke, Frank
Reference:
S. Lefere, L. Devisscher and F. Tacke, "Targeting CCR2/5 in the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis", Expert opinion on investigational drugs, vol. 29, no. 2, 2020, pp. 89–92.
BibTeX Entry:
@article{Lefere:788068,
  author       = {Lefere, Sander and Devisscher, Lindsey and Tacke, Frank},
  title        = {Targeting {CCR}2/5 in the treatment of nonalcoholic steatohepatitis ({NASH}) and fibrosis},
  journaltitle = {Expert opinion on investigational drugs},
  year         = {2020},
  doi          = {10.1080/13543784.2020.1718106},
  keywords     = {,CRC1382-Project B05},
  location     = {Abingdon, Oxon},
  note         = {SFB 1382: Die Darm-Leber-Achse -- Funktionelle Zusammenhänge und therapeutische Strategien (403224013)},
  number       = {2},
  pages        = {89--92},
  publisher    = {Routledge, Taylor \& Francis},
  pubmed       = {pmid:31952447},
  reportid     = {RWTH-2020-04416},
  subtitle     = {Opportunities and challenges},
  url          = {https://publications.rwth-aachen.de/record/788068},
  volume       = {29},
}